FDA approved its citrate and calcium solutions for adults and children weighing at least 40 kg; controlled U.S. rollout precedes full availability.

Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, presents new research ...

Fresenius Medical Care Presents New Research And Evidence-Driven Innovations Aimed At Improving Patient Outcomes During ASN Kidney Week 2026 CI Oct. 19 Fresenius Medical Care AG : Deutsche Bank ...

Fresenius Medical Care AG is the world's leading supplier of services and equipment for patients with kidney problems. Net sales break down by activity as follows: - clinical care services (75.2%): ...

Fresenius Medical Care is presenting U.S. clinical research and technology-focused studies at ASN Kidney Week 2026 in Denver, October 21–25. Findings include real-world delivery ...

The health system in the Gaza Strip is facing unprecedented crisis with declining hospital capacity, breakdown of medical ...

A retrospective series of 11 patients with liver failure found low-dose regional citrate combined with nafamostat feasible ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

DaVita (DVA) and Fresenius Medical Care (FMS), the leading dialysis providers in the U.S., traded lower on Tuesday after Axios reported that the Trump administration is planning to encourage ...

DaVita (DVA) stock sank 6% on Trump’s Kidney Care National Plan news—see market impact, key metrics, and what to watch ahead ...

HHS kidney plan takes aim at dialysis market concentration, targeting DaVita and Fresenius' 74% market share to improve care and competition.